At its Oct. 9 H1 2026 results briefing, Bloomage BioTechnology said it is
expanding beyond its hyaluronic acid strength into PDRN/PN, recombinant
collagen, human milk oligosaccharides (HMOs), ergothioneine and salidroside.
Some of those new bioactives have entered commercialization and have begun to
contribute revenue. In the raw-materials segment, PDRN and recombinant collagen
are gradually becoming new growth drivers.